Nanobiotix Shares Decline Despite a 800% Surge Over the Year
Nanobiotix shares fell by 2.63% this Tuesday morning to 26.68 euros, following a previous close at 27.40 euros. This decline comes even as the French biotech has shown an impressive performance of over 800% over the past year, driven by a remarkable stock market trajectory in recent quarters.
Current Session Performance
In the current session, Nanobiotix is trading at 26.68 euros, down by 2.63% compared to the last close. The stock has gained nearly 54.76% over the past three months and has shown a spectacular increase of 802.6% over the past year. This long-term upward momentum contrasts with today's decline, in an otherwise bullish Parisian market environment: the CAC 40 is up by 1.33% at 8,068 points, and the SBF 120 is similarly up by 1.33%. In the healthcare sector, performances are mixed: Sanofi is up by 0.85%, while UCB is down by 1.36%. Nanobiotix's decline is moderate considering its monthly volatility of 23.35%, and its low beta of 0.16, indicating limited correlation with general market movements.
Technical Analysis Overview
From a technical analysis perspective, Nanobiotix's stock price is currently above its 50-day moving average of 23.91 euros and significantly above its 200-day moving average of 15.74 euros, confirming a medium and long-term bullish trend. However, the stock is lagging behind its 20-day moving average at 27.98 euros, suggesting a slight short-term fatigue. The RSI stands at 54, in a neutral zone, far from overbought or oversold thresholds. Bollinger Bands frame the price between 23.67 euros (lower bound) and 32.28 euros (upper bound): the stock is trading in the middle part of this channel, without extreme tension signals. The next resistance threshold is at 33.50 euros, while the nearest support is identified at 21.30 euros, offering a significant gap from the current price.
